Join the Saxenda group to help and get support from people like you.
Saxenda News
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
One in Five State Medicaid Programs Cover Antiobesity Medications
THURSDAY, March 21, 2024 – As of early 2023, one in five state Medicaid programs covered antiobesity medications, according to a research letter published online March 14 in the Journal of the ...
Exercise Key to Maintaining Weight Loss After Stopping GLP-1 Receptor Agonists
MONDAY, March 4, 2024 – The addition of supervised exercise to obesity pharmacotherapy improves healthy weight maintenance after treatment termination, according to a study published online Feb. 19...
Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects
TUESDAY, Jan. 16, 2024 – Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
FRIDAY, Oct. 6, 2023 – Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel obstruction compared...
Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...
European Regulators Investigating Risk for Suicidal Thoughts With Popular Weight-Loss Drugs
TUESDAY, July 11, 2023 – The European Medicines Agency is investigating concerns that popular weight-loss drugs like Ozempic and Saxenda may be linked to suicidal thoughts and thoughts of self-harm....
Semaglutide Better Than Liraglutide for Post-Bariatric Surgery Weight Recurrence
WEDNESDAY, June 7, 2023 – Semaglutide is associated with superior weight loss for treating post-metabolic and bariatric surgery (MBS) weight recurrence compared with liraglutide, according to a...
Wegovy, Saxenda Help Folks Lose Pounds They Regained After Weight-Loss Surgery
MONDAY, June 5, 2023 – When people regained weight after obesity surgery, it wasn’t entirely clear what to do next. Now, it appears the weight-loss medications Wegovy and Saxenda can help. Both work ...
FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight)